Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 2,800 shares at $20.03 ($56K) on 2025-09-23, disclosed to the SEC on 2025-09-25.
Scheduled sale ($56k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |
| ELVN | SELL | 2025-08-21 | $30K | — | Filing → |